Skip to main content

Table 2 Compliance of S-1 for each course

From: Safety and feasibility of adjuvant chemotherapy with S-1 in Japanese breast cancer patients after primary systemic chemotherapy: a feasibility study

Cycle number

Completion rate in the eligible patients

Reasons for discontinuation of treatment (The number of patients)

1

97.7%(42/43)

Adverse event(1)

2

93.0%(40/43)

Patient refusal(2)

3

90.7%(39/43)

Adverse event(1)

4

86.0%(37/43)

Patient refusal(2)

5

74.4%(32/43)

Patient refusal(3)

Adverse event(1)

Recurrence(1)

6

69.8%(30/43)

Patient refusal(1)

Recurrence(1)

7

69.8%(30/43)

 

8

69.8%(30/43)

 

9

62.8%(27/43)

Patient refusal(1)

Recurrence(2)

10

32.8%(27/43)

 

11

60.5%(26/43)

Recurrence(1)

12

60.5%(26/43)

 

13

55.8%(24/43)

Adverse event(1)

Recurrence(1)

14

51.2%(22/43)

Adverse event(1)

Recurrence(1)

15

51.2%(22/43)

 

16

51.2%(22/43)

 

17

51.2%(22/43)

 

18

51.2%(22/43)